Senexin B

CAS No. 1449228-40-3

Senexin B ( SNX2-1-165 )

Catalog No. M11929 CAS No. 1449228-40-3

Senexin B (SNX2-1-165) is a highly potent, selective and orally available CDK8/CDK19 inhibitor with IC50 of 24-50 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 248 In Stock
10MG 372 In Stock
25MG 620 In Stock
50MG 881 In Stock
100MG 1188 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Senexin B
  • Note
    Research use only, not for human use.
  • Brief Description
    Senexin B (SNX2-1-165) is a highly potent, selective and orally available CDK8/CDK19 inhibitor with IC50 of 24-50 nM.
  • Description
    Senexin B (SNX2-1-165) is a highly potent, selective and orally available CDK8/CDK19 inhibitor with IC50 of 24-50 nM; exhibits selectivity for CDK8 and CDK19 with Kd of 140 nM and 80 nM, respectively; significantly suppresses tumor growth in ER-positive breast cancer xenografts.
  • Synonyms
    SNX2-1-165
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1449228-40-3
  • Formula Weight
    450.53
  • Molecular Formula
    C27H26N6O
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    O=C(C1=CC2=CC=C(CCNC3=C4C(C=CC(C#N)=C4)=NC=N3)C=C2C=C1)N5CCN(C)CC5
  • Chemical Name
    4-((2-(6-(4-Methylpiperazine-1-carbonyl)naphthalen-2-yl)ethyl)amino)quinazoline-6-carbonitrile

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Donald C. Porter, et al. Abstract PR08: Targeting tumor microenvironment with selective small-molecule inhibitors of CDK8/19.

2. Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer. Publication number: WO2013116786 A1.

3. McDermott MS, et al. Oncotarget. 2017 Feb 21;8(8):12558-12575.
molnova catalog
related products
  • SB415286

    SB415286 is a potent GSK3α inhibitor with IC50/Ki of 78 nM/31 nM with equally effective inhibition of GSK-3β.

  • (R)-CR8

    (R)-CR8 is a potent and selective CDK inhibitor.A delayed systemic post-LFP administration at 3 hours of CR8--a potent second-generation cyclin-dependent kinase (CDK) inhibitor.

  • PF07104091

    PF-07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.